19

2025-06


Minhai Bio Unites “Min” Hearts in 2025, Striding Toward the Future: The MINI Marathon Relay Concludes Successfully

On the afternoon of June 6, 2025, the MINI Marathon Relay—themed “Uniting the ‘Min’ Spirit, Striding Toward the Future”—concluded successfully on the plaza in front of Building No. 1 at Minhai Biologics’ International Vaccine Industrial Base. Employees’ enthusiastic spirit and collaborative teamwork highlighted the company’s dynamic, forward‑looking corporate culture. At the opening ceremony, General Manager Nie delivered a speech, underscoring the company’s people‑oriented development philosophy and encouraging staff to relieve stress and strengthen team cohesion through physical activity. Following the start of the race, participating teams quickly found their rhythm. A professional coach led the warm‑up session, ensuring that employees were in peak condition for the competition; the event itself was lively and engaging, with each team showcasing their ingenuity…

16

2025-06


Public Notice of Proposed Nominations for the 2025 National Science and Technology Awards (Technical Invention Award)

1. Project Name: Key Technologies for the Development of a Superbug Vaccine and Their Promotion and Application 2. Nominating Entity: Chongqing Municipality 3. Category and Level of Nomination Award: National Invention Award—First Prize or Second Prize 4. List of Major Intellectual Property Rights, Standards, and Specifications: | Intellectual Property (Standard) Category | Specific Name of Intellectual Property (Standard) | Country (Region) | Authorization Number (Standard Number) | Date of Authorization (Standard Publication) | Certificate Number (Standard Approval and Publication Authority) | Right Holder (Standard Drafting Organization) | Inventor (Standard Drafter) | Patent (Standard) | Validity Status | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Invention Patent (Standard) | A Staphylococcus aureus Vaccine and Its Preparation Method | China | ZL2 |

16

2025-06


Public Notice Regarding Nomination Projects for the 2025 National Science and Technology Awards

Public Notice Regarding Nominations for the 2025 National Science and Technology Awards In accordance with Document No. 4 [2025] issued by the National Science and Technology Awards Office, “Notice on the Nomination Process for the 2025 National Science and Technology Awards,” and in order to ensure the smooth submission of applications for the 2025 National Science and Technology Awards, uphold the fairness of the awards, and strengthen public oversight of scientific and technological award activities, we hereby announce the project “Key Technologies for the Development of a Superbug Vaccine and Its Promotional Application,” in which our company has participated. The public notice period is from June 16 to June 20, 2025. During this period, should you have any objections to the nominated project, please submit your concerns to…

10

2025-06


First Public Disclosure of the Environmental Impact Assessment for the “Production Workshop Construction Project of Minhai Biotechnology’s Quadrivalent Inactivated Enterovirus Vaccine (Vero Cell)”

In accordance with the requirements of the Measures for Public Participation in Environmental Impact Assessment (Order No. 4 of the Ministry of Ecology and Environment), the following information regarding the environmental impact assessment for the “Construction Project of the Production Workshop for Minhai Biotechnology’s Quadrivalent Inactivated Enterovirus Vaccine (Vero Cell)” is hereby made public: I. Project Overview Project Name: Construction of the Production Workshop for Minhai Biotechnology’s Quadrivalent Inactivated Enterovirus Vaccine (Vero Cell) Project Nature: Expansion Construction Site: Building No. 2, Zone 2B, North Factory Area, Beijing Minhai Biotechnology Co., Ltd., No. 35 Simiao Road, Bio‑Pharmaceutical Industry Base, Daxing District, Beijing Project Undertaker: Beijing Minhai Biotechnology Co., Ltd. Scope of Construction: This project will utilize…

30

2025-04


Nie Xiaoqi, Deputy General Manager of Minhai Biotechnology, has been honored as a 2025 Beijing Model Worker!

On April 29, the Beijing Municipal Conference on Commending Model Workers, Advanced Workers, and Exemplary Collectives was solemnly held at the Beijing Convention Center. With approval from the CPC Beijing Municipal Committee and the Beijing Municipal People’s Government, Nie Xiaoqi, Deputy General Manager of Minhai Biotechnology, was awarded the honorary title of “Beijing Model Worker for 2025.” This year’s commendation placed particular emphasis on recognizing knowledge-based, skill‑driven, and innovation‑oriented workers, focusing on the capital’s major strategic priorities and key industries. Thanks to his outstanding contributions in vaccine production and quality management, Mr. Nie emerged as one of the distinguished representatives honored in the pharmaceutical and healthcare sector. For many years, Mr. Nie has been deeply committed to vaccine industrialization and quality assurance, successively holding positions in production management…

< 1...567...43 >